title: Hard palate perforation: an unusual finding in paracoccidioidomycosis.
abstract: A 36-year-old black man presented to his dermatologist in May 1996 complaining of mucosal lesions in the mouth, as well as perforation of the hard palate. The lesions had started approximately 7 months before and had worsened gradually. Other complaints included odynophagia, dysphagia, mild dyspnea, and dry cough. The patient was in good general health, but reported a 3 kg weight loss over the previous semester. The hard and soft palate presented erythematous ulcers with a finely granulated base and irregular, but clearly defined margins. A perforation (diameter, 0.5 cm) of the hard palate was seen in the center of the ulcerated region (Fig. 1). Direct examination of 10% KOH cleared specimens showed typical double-walled, multiple budding yeast structures. Paracoccidioidomycosis (PCM) serologic reactions tested positive for double immunodiffusion (DI), complement fixation (CF) 1 : 256 and counterimmunoelectrophoresis (CIE) 1 : 128. Hematoxylin and eosin-stained sections of oral lesions showed an ulcer covered by a fibrous leukocytic crust, with a lymphoplasmacytic infiltrate, as well as multinuclear giant cells containing round bodies with a double membrane. Gomori-Grocott staining showed budding and blastoconidia suggestive of PCM. Lung computed tomography (CT) exhibited findings consistent with pulmonary PCM. Diagnosis of the chronic multifocal form of PCM with oral and pulmonary manifestations was established. Drug therapy was initiated with ketoconazole (KCZ) 200 mg twice daily, which led to clinical cure in approximately 2 months. Serum antibody values rose 30 days after institution of therapy (CIE 1 : 256; CF 1 : 512), peaking at day 60 (CIE 1 : 1024; CF 1 : 1024). Three months later the daily dose was reduced to 200 mg and titers declined slowly. The diameter of the perforation remained unchanged (Fig. 2). The hard palate perforation was corrected with a palatoplasty 27 months after initiation of drug therapy (Fig. 3). KCZ was discontinued when serologic cure was achieved after 34 months of treatment (DI weakly positive; CIE 1 : 8; CF not measurable). The patient was discharged 46 months after the first visit.
authors.affiliation: Division of Dermatology, Hospital das Clínicas, Schools of Medicine and Dentistry, University of São Paulo, R. Mato Grosso 128 cj 34, São Paulo/SP, 01239-040 Brazil. guiga@dermamail.com.br
authors.forename: L G
authors.initials: LG
authors.lastname: Castro
authors.forename: A P
authors.initials: AP
authors.lastname: Müller
authors.forename: M A
authors.initials: MA
authors.lastname: Mimura
authors.forename: D A
authors.initials: DA
authors.lastname: Migliari
mesh_terms: D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D019647:Oral Surgical Procedures; D021362:Palate, Hard / Q000382:microbiology / Q000473:pathology* / Q000601:surgery; D010229:Paracoccidioidomycosis / Q000188:drug therapy / Q000382:microbiology*; D004718:Saccharomycetales / Q000187:drug effects
chemical_list: D000935:Antifungal Agents; D007654:Ketoconazole